InvestorsHub Logo
Followers 494
Posts 32009
Boards Moderated 0
Alias Born 03/12/2014

Re: None

Monday, 06/20/2022 12:34:21 PM

Monday, June 20, 2022 12:34:21 PM

Post# of 8923
Big news coming this week!
Fasten your seat belt

9:00a ET 6/17/2022 - Globe Newswire
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
Mentioned: CAPR
EQNX::TICKER_START (NASDAQ:CAPR), EQNX::TICKER_END Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that the Company will present one-year, safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD) at this year's Parent Project Muscular Dystrophy (PPMD) Annual Conference.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CAPR News